WallStSmart

Healthcare Triangle Inc (HCTI)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 259186% more annual revenue ($66.57B vs $25.67M). MRK leads profitability with a 4.8% profit margin vs -66.3%. HCTI earns a higher WallStSmart Score of 41/100 (D).

HCTI

Hold

41

out of 100

Grade: D

Growth: 5.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -2.84

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HCTI.

MRKSignificantly Overvalued (-78.2%)

Margin of Safety

-78.2%

Fair Value

$83.04

Current Price

$149.32

$66.28 premium

UndervaluedFair: $83.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCTI3 strengths · Avg: 9.7/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
158.4%10/10

Revenue surging 158.4% year-over-year

Debt/EquityHealth
0.269/10

Conservative balance sheet, low leverage

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$365.34B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

HCTI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$11.39M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-26.5%2/10

ROE of -26.5% — below average capital efficiency

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.8x4/10

Trading at 8.8x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : HCTI

The strongest argument for HCTI centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 158.4% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : HCTI

The primary concerns for HCTI are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

HCTI profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

HCTI carries more volatility with a beta of 1.09 — expect wider price swings.

HCTI is growing revenue faster at 158.4% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

HCTI scores higher overall (41/100 vs 36/100) and 158.4% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Healthcare Triangle Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Healthcare Triangle, Inc. is a healthcare information technology company. The company is headquartered in Pleasanton, California.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?